----item----
version: 1
id: {CF23E940-BE0E-4FF7-A55B-8B5AF7E35EEB}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/01/Antares sinks on FDA safety data request
parent: {684FC8D5-D802-45B5-B1B4-59D6EC33E6A8}
name: Antares sinks on FDA safety data request
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: d2adbe4b-4a80-4bf8-a693-361ef7d10034

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 40

Antares sinks on FDA safety data request
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 40

Antares sinks on FDA safety data request
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1600

<p>Shares of Antares Pharma dropped more than 11% in morning trading on 13 January after the company revealed the FDA wants the firm to create a larger safety database for its experimental drug QuickShot Testosterone after a single reported case of hives in a Phase II study participant.</p><p>The company, which said it did not believe the hives case was related to QuickShot, said the FDA's request could have an impact on the timing of the firm's new drug application filing for QuickShot. </p><p>Based on the number of participants in previous studies and in the current Phase III trial, Antares said it anticipates that it may need about 70 additional subjects exposed to the drug for six months. </p><p>The biotech said it was assessing the FDA's comments, which came in the form of an advice letter. </p><p>Antares said it continues to expect to release top-line pharmacokinetic data from the Phase III study in the second quarter.</p><p>The company said it believes it already has factored many of the FDA's recommendations into the protocol of the ongoing Phase III study and into the protocols for planned human use studies as a result of guidance provided by the agency at the May 2014 "Type C" meeting. </p><p>The double-blind, multiple-dose, Phase III study is evaluating the efficacy and safety of QuickShot administered subcutaneously once each week to 150 testosterone-deficient adult males. </p><p>Patients enrolled in the trial had a documented diagnosis of hypogonadism or testosterone deficiency defined as having repeated testosterone levels below 300ng/dL.</p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 291

<p>Shares of Antares Pharma dropped more than 11% in morning trading on 13 January after the company revealed the FDA wants the firm to create a larger safety database for its experimental drug QuickShot Testosterone after a single reported case of hives in a Phase II study participant.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 40

Antares sinks on FDA safety data request
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150901T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150901T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150901T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC027512
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 40

Antares sinks on FDA safety data request
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

pdfNewsLetter
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

356036
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042231Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

d2adbe4b-4a80-4bf8-a693-361ef7d10034
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042231Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
